Less Than First: Below-Average Innovation In US FDA’s Big 2023 Novel Approval Haul

 
• By Bridget Silverman

Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.

below average
The US FDA approval class of did not get strong marks in some areas. • Source: Shutterstock

More from Approvals

More from Product Reviews